Drug development

#Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #Immunology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pharmokinetics #RNA #Sequencing

The Case for Multiplex Protein Assays

The Case for Multiplex Protein Assays By Dr Robert Huang and Dr Diem Nguyen Multiplex testing has gained a growing popularity among scientists, mainly due to financial and competitive pressures forcing companies to narrow their targets and validate their leads as quickly as possible. We discuss how multiplex assays can… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Pharmacology #Pharmokinetics #Regulatory #RNA #Screening #Target validation #Toxicology

Applications of liquid chromatography mass spectrometry

Applications of liquid chromatography mass spectrometry By Dr David Kwok Applications of liquid chromatography mass spectrometry in accelerating the pace of lead-drug candidate selection and pre-clinical development. This review discusses how the application and benefits of using LC/MS and LC/MS/MS assays in conjunction with in vivo and in vitro study… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analytical chemistry #Automation / robotics #Business #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Pathology #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Translational #Translational chemistry

Structural Genomics drives demand for high throughput protein purification

Structural Genomics drives demand for high throughput protein purification By Karsten Fjarstedt The rapid growth in proteomic and structural and functional genomic research is driving demand for purified proteins that far exceeds the industry's ability to scale-up conventional protein production technologies. This demand has sparked innovation in protein separation and… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Microfluidics #Protein chemistry / Proteomics #RNA #Screening #Stem cells

Expanding the profile of Kinase Panels

Expanding the profile of Kinase Panels By Dr John Comley With little sign of a decline in Pharma interest in kinase targets, greater emphasis is now being directed towards kinase selectivity profiling. A recent industry market survey suggests that although the market for kinase primary screening reagents is estimated to… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Gene therapy #Genomics #Lead discovery #Lead optimisation #Patent Law #Pharmacology #Preclinical #Screening #Stem cells #Therapeutics

Failure rates in drug discovery and development: will we ever get any better?

Failure rates in drug discovery and development: will we ever get any better? By William Bains Drug discovery is an expensive, slow and risky business. An analysis which takes into account projects which neither succeed nor fail suggests that it costs more than $1 billion to launch a technically successful… Read More

#Archive

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development

Getting Property Strategy Right in Biotech

Getting Property Strategy Right in Biotech By Martin Sylvester The global biotech industry is, according to a recent report by Ernst & Young, 'turning up' despite a relatively subdued recent climate. Recovery in the biotech sector during 2003 was almost six months ahead of predictions and overall growth continues apace. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Pathology #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

Functional screening of viral siRNA libraries in human primary cells

Functional screening of viral siRNA libraries in human primary cells By Dr Kara Bortone, Dr Frits Michiels, Dr Nick Vandeghinste, Dr Peter Tomme and Dr Helmuth van Es One of the major challenges facing the pharmaceutical industry today is the identification and validation of novel, high-quality drugable targets in underserved… Read More

#Archive

#Analysis #Animal models #Biochemistry #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #Imaging #Lead discovery #Pathology #PCR #Pharmacology #RNA #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Novel concepts and therapeutic options for the treatment of schizophrenia

Novel concepts and therapeutic options for the treatment of schizophrenia By Dr Karoly Nikolich and Dr Roman Urfer Schizophrenia affects a large number of individuals irrespective of social status and education. Current treatments of schizophrenia represent the second largest central nervous system (CNS) pharmaceutical market, exceeding $12 billion per year. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Automation / robotics #Biomarkers #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #Lead discovery #Medicinal chemistry #Metabolomics #Molecular medicine #Pharmacology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Toxicology

Metabonomics – A generic platform for the investigation of drug toxicity, altered gene function and disease processes

Metabonomics - A generic platform for the investigation of drug toxicity, altered gene function and disease processes By Professor Jeremy K. Nicholson Metabonomics can offer one of the most complete solutions to tackling one of the pharmaceutical industry's biggest problems attrition. This article discusses the scope and uses of metabonomics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #PCR #RNA #Screening #Stem cells

Continued miniaturisation of assay technologies drives market for nanolitre dispensing

Continued miniaturisation of assay technologies drives market for nanolitre dispensing By Dr John Comley The continued miniaturisation of assay technologies in high throughput screening, compound management and protein crystallisation has created a pressing need for improved nanolitre liquid handling systems. A recent industry market survey suggests that although the total… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Pathology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Systems Biology – Precise phenotypic anchoring for drug target identification, validation and biomarker discovery

By Dr Peter C. Johnson and Dr Alan J. Higgins The pharmaceutical industry has not seen the hoped-for productivity gains from the various omics datastreams over the last decade. This article discusses how systems biology can exploit the natural interlinkages between these datastreams and put in place a powerful system… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microfluidics #Oncology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Target validation #Therapeutics #Toxicology

The Current Bioinformatics Analytical Software Landscape

The Current Bioinformatics Analytical Software Landscape By Charles Chang With the vast amount of biochemical data generated from experiments conducted by research laboratories around the globe, there is strong demand for software to analyse and manage the data effectively. Analytical software can be utilised to analyse virtually every single experiment,… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Medicinal chemistry #PCR #Pharmacology #Pharmokinetics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics

Virtual Screening – Finding needles in a haystack on a shoestring

Virtual Screening - Finding needles in a haystack on a shoestring By Dr David E. Clark, Neil V. Harris, Alan G. Roach and Dr Anthony D. Baxter In recent years, virtual screening (VS) has become an accepted approach to hit-finding alongside biochemical high-throughput screening (HTS). Large pharmaceutical companies are typically… Read More

#Archive

#AI / data analytics / healthtech / informatics #Business #Clinical trials #Drug development #Drug discovery #Immunology / Virology & Vaccines #Lead discovery #Pharmacology #Regulatory #RNA

How can we build sustainable European biopharmaceutical companies?

By Professor Simon Turton, Henry Makansi and Nick Lowcock Business models for emerging bioscience companies come in and out of fashion with some regularity, not always with obvious reason. This article examines what strategies have worked for the leading biopharmaceutical firms in Europe to try to identify what lessons there… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biochemistry #Business #Chemical engineering #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microfluidics #Molecular medicine #Patent Law #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Tools for Structural Genomics – Accelerating the structure pipeline

Share Share Tweet Email Tools for Structural Genomics - Accelerating the structure pipeline Tools for Structural Genomics - Accelerating the structure pipeline By Dr Lawrence J. DeLucas, Dr Christie G. Brouillette, Dr Kal Ramnarayan and Dr Shankari Mylvaganam The international structural genomics effort has resulted in a number of technological… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Chemical engineering #Chemistry #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Organic chemistry #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

Opportunities for the pharmaceutical industry: key biotransformation technologies of the future

Opportunities for the pharmaceutical industry: key biotransformation technologies of the future By Praveen Kaul, Anirban Banerjee and Professor UC Banerjee Biotransformation is a broad and growing field of biotechnology and encompasses both enzymatic and microbial biocatalysis. Progress has been made in research on the key drivers of biotransformations, including the… Read More

#Archive